Informational to commercial bridge • 3 min read • Published 2026-04-14 • Updated 2026-04-14
15 Questions to Ask Before Starting a GLP-1 Program
Use this checklist to make a safer, clearer GLP-1 decision before you commit to any program.
By CareBareRX Editorial Team (Affiliate-health writers focused on GLP-1 patient education, evidence summaries, and consumer decision frameworks.)
Evidence reviewed (editorial process): 2026-04-14
Review standards: Editorial Policy · Evidence Review Policy
Key Takeaways
- Many buyers focus on one question: "How much weight might I lose?" The better approach is to ask safety, eligibility, and process questions first.
- Am I clinically eligible for this pathway right now?
- What are the most common side effects in early weeks?
- Who manages ongoing care and follow-up decisions?
- What is a realistic first-12-week expectation for someone like me?
Decision Checklist
Use this quick table to pressure-test fit before taking action.
| Criterion | What to Verify | Why It Matters |
|---|---|---|
| Total Cost | First-90-day all-in estimate in writing | Prevents month-2 and month-3 surprises |
| Clinical Clarity | Who prescribes, who follows up, who escalates | Sets realistic safety and communication expectations |
| Fulfillment | Refill timeline and delay/replacement policy | Protects continuity during normal disruptions |
| Policy Terms | Cancellation and pause policy in plain language | Reduces lock-in and checkout regret risk |
Why this checklist matters
Many buyers focus on one question: "How much weight might I lose?" The better approach is to ask safety, eligibility, and process questions first.
GLP-1 decisions are medical decisions. A clean question list helps you compare programs, reduce risk, and avoid preventable confusion.
Eligibility and medical history questions
- Am I clinically eligible for this pathway right now?
- Do any of my existing conditions change your recommendation?
- How do my current medications affect this plan?
- What symptoms should trigger urgent medical follow-up?
- What baseline information do you need before starting?
Safety and side-effect questions
Systematic evidence suggests GI adverse events are common, especially early in treatment. That does not mean everyone has severe symptoms, but it does mean planning for monitoring is essential.
- What are the most common side effects in early weeks?
- Which side effects are expected vs red-flag symptoms?
- How should dose changes be handled if tolerability is poor?
- How do you monitor GI or gallbladder-related concerns?
- When should treatment be paused or stopped?
Explore GLP-1 Options From $199/mo
CareBareRX is an affiliate referral site connecting you to third-party licensed providers. No insurance is required for many pathways.
Get Started TodayProgram and logistics questions
- Who manages ongoing care and follow-up decisions?
- How fast are refill requests processed?
- What happens if medication supply is delayed?
- What is included in my monthly fee?
- How do I cancel or pause if needed?
Expectation-setting questions
- What is a realistic first-12-week expectation for someone like me?
- How will we define success besides scale weight?
- What is the plan if progress plateaus?
- What is the long-term maintenance strategy?
- How will we revisit route choice (oral vs injectable) if adherence is poor?
Share This Guide
Send this article to someone comparing GLP-1 options.
Next Step
Use this framework, then compare current options and verify full details before starting.
Start with a provider-reviewed optionResearch Citations
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (Gastroenterology, 2022) Source
- Chiang CH, et al. GLP-1 receptor agonists and gastrointestinal adverse events: systematic review/meta-analysis (Gastroenterology, 2025) Source
- FDA: Compounding risk alerts (includes semaglutide dosing-error alert) Source
- NIDDK: Prescription medications to treat overweight and obesity Source
- FTC: Health Products Compliance Guidance Source
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM, 2021) Source
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022) Source
Related Guides
Explore Topic Hubs
Medical Disclaimer
This content is educational and is not medical advice. CareBareRX is an affiliate referral website and not a healthcare provider. Eligibility, prescribing, and treatment decisions must be made by a licensed healthcare provider.